Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure–Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives
Citations Over TimeTop 10% of 2011 papers
Abstract
The phosphoinositide 3-kinase (PI3K) family catalyzes the ATP-dependent phosphorylation of the 3'-hydroxyl group of phosphatidylinositols and plays an important role in cell growth and survival. There is abundant evidence demonstrating that PI3K signaling is dysregulated in many human cancers, suggesting that therapeutics targeting the PI3K pathway may have utility for the treatment of cancer. Our efforts to identify potent, efficacious, and orally available PI3K/mammalian target of rapamycin (mTOR) dual inhibitors resulted in the discovery of a series of substituted quinolines and quinoxalines derivatives. In this report, we describe the structure-activity relationships, selectivity, and pharmacokinetic data of this series and illustrate the in vivo pharmacodynamic and efficacy data for a representative compound.
Related Papers
- → The Chemistry and Applications of the Quinoxaline Compounds(2019)28 cited
- → Quinoxaline Macrocycles(2014)9 cited
- → Recent Advances on the Synthesis, Reactions and Evaluation of the Pharmacological Properties of Quinoxaline, Quinoxaline-2-One and Quinoxaline-2,3-Dione(2021)1 cited
- Synthesis of Mercaptoalkoxy quinoline Compounds(2002)
- → Carcinogenic Activity of Analogues of <italic>p</italic>-Dimethylaminoazobenzene. IV. Activity of the Quinoline Analogues<xref ref-type="fn" rid="FN1">2</xref>(1961)